Amylyx provides update on Compassionate Access for AMX0035 in France

Amylyx announced thatL’Agence Nationale de Securite du Medicament et des produits de sante – ANSM -, the national authority for authorizing medicinal products in France, has granted “acces compassionnel”, or compassionate access, to AMX0035 for eligible people living with amyotrophic lateral sclerosis – ALS – following a collaborative process involving medical experts, ARSLA and other ALS advocates, ANSM, and Amylyx. AMX0035 is known as Relyvrio in the U.S. and Albrioza in Canada. Separately, the formal re-examination procedure of the Marketing Authorisation Application of AMX0035 for the treatment of adults with ALS in the EU remains underway.